Vir Biotechnology Inc. has announced the initiation of a Phase 1 clinical trial for VIR-5525, an investigational dual-masked T-cell engager targeting the epidermal growth factor receptor (EGFR). The study will assess the safety, pharmacokinetics, and preliminary anti-tumor activity of VIR-5525 as both a monotherapy and in combination with pembrolizumab. The trial aims to address EGFR-expressing solid tumors, such as non-small cell lung cancer, colorectal cancer, head and neck squamous cell carcinoma, and cutaneous squamous cell carcinoma. Initial results from this trial have not yet been presented. The development of VIR-5525 is part of Vir Biotechnology's efforts to provide innovative therapies for hard-to-treat cancers, utilizing the PRO-XTEN™ platform to improve therapeutic outcomes.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。